Petitioners seeking the use of “march-in” rights to obtain lower pricing on Astellas’s prostate cancer drug Xtandi (enzalutamide) may not have been successful in their appeal, but did obtain HHS recognition of the need to evaluate pricing in the use of march-in rights.
Source: Drug Industry Daily